Navigation Links
Phase 3 Trial Shows Denosumab Delayed Skeletal Related Events in Advanced Cancer Patients With Bone Metastases
Date:9/21/2009

ates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting ph
'/>"/>

SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  The Academy ... Food and Drug Administration,s (FDA,s) draft guidance and ... products and biosimilars, to bear a nonproprietary name ... has been seeking a decision from the FDA ... diverse health care stakeholders urging the agency to ...
(Date:8/27/2015)... Aug. 27, 2015  A recent study by ... Journal, compared the Arthrosurface HemiCAP® Wave implant, which ... an "onlay" design implant for isolated patellofemoral disease. ... function and pain scores, none of the patients ... (OA). However, 53% of the patients in the ...
(Date:8/27/2015)... Aug. 27, 2015 DURECT Corporation (Nasdaq: ... present at three upcoming healthcare conferences.  ... will present at the Rodman & Renshaw Investment Conference ... The conference is being held at the St. Regis ... A live audio webcast of the presentation will be ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3DURECT to Participate in Upcoming Healthcare Conferences 2
... Sept, 21 OmniComm Systems, Inc. (OTC ... of eClinical solutions and services announced that it will ... at the Hilton Beach Resort in Fort Lauderdale, Florida ... presentations and speakers from participating Life Science organizations. The ...
... The Pittsburgh Life Sciences Greenhouse (PLSG), the ... and business growth programs to western Pennsylvania,s life ... nationally recognized Executives-in-Residence (EIR) has launched a new ... (Ib2C(TM)). Ib2C(TM) Founder and CEO, Stephen ...
Cached Medicine Technology:OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 2OmniComm Systems, Inc. Hosts Autumn 2010 eClinical Forum Meeting 3Pittsburgh Life Sciences Greenhouse Executive-in-Residence Launches Medical Device Company 2Pittsburgh Life Sciences Greenhouse Executive-in-Residence Launches Medical Device Company 3Pittsburgh Life Sciences Greenhouse Executive-in-Residence Launches Medical Device Company 4
(Date:8/27/2015)... ... 27, 2015 , ... Keck Graduate Institute (KGI), School of Pharmacy celebrated its ... a formal ceremony recognizing them as members of the 2nd class of the KGI ... Symbolizing dedication to clinical service and patient care, the White Coat Ceremony is held ...
(Date:8/27/2015)... ... 2015 , ... According to an article published August 21st on ... the success of a patient who is attempting to lose weight. Specifically, the trial ... over that period, and compared those results with how helpful each patient felt their ...
(Date:8/27/2015)... ... ... Mesa Community College graduate, Andrew Sypher (Mesa), is one of 10 ... and engagement, to receive a Phi Theta Kappa 2015 Hites Transfer Scholarship, to assist ... a $7,500 scholarship to assist in his goal of becoming a foreign diplomat with ...
(Date:8/27/2015)... ... August 27, 2015 , ... In the addiction treatment industry, some patients go ... relapsing and returning again, all at great cost to them and their families. Others ... or soon after leaving facilities who claim to have given addicts tools to overcome ...
(Date:8/27/2015)... ... August 27, 2015 , ... According to the Rocky ... patient with hemophilia is $175,000. Hemophilia is an inherited, life-long condition with no ... RMHBDA exists to help raise funds for patients suffering from bleeding disorders, deliver ...
Breaking Medicine News(10 mins):Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 2Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 3Health News:KGI School of Pharmacy’s 2nd Annual White Coat Ceremony a Success 4Health News:Article on Physician Influence on Weight Loss Highlights the Importance of a Doctor Who Cares, says Dr. Feiz & Associates 2Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 2Health News:Mesa Community College Graduate Andrew Sypher Receives Hites Transfer Scholarship 3Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 2Health News:National Screenings of Documentary Indicate Burgeoning Questions about the Effectiveness of Addiction Treatment Facilities 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 2Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 3Health News:Avitus Group Encourages Business & Employee Community Involvement; Senior Level Staff Leads Way With Support of Rocky Mountain Hemophilia & Bleeding Disorders Association 4
... at Monash University in Australia have developed a process for ... without any moving parts, potentially allowing doctors //to do blood ... new method uses the same principle that causes tea leaves ... stirred teacup, a phenomenon first explained by Einstein in the ...
... in a worldwide research have come up with a microbicidal ... is expected to evolve into a powerful new protection weapon ... be 95% efficient. ,Brazilian scientists, who aim ... microbicides , assure the gel will be on the market ...
... cancer death in the U.S.; more than 30,000 Americans are ... ,Pancreatic cancer is an extremely difficult cancer to treat and ... factor in pancreatic cancer is cigarette smoking; other links have ... In a new study, researchers at the Harvard School of ...
... fatal, at the hands of stomach cancer, according to experts. ... rest a mystery of 200 years, // regarding the cause ... recent theory, running since the 1961 discovery of arsenic in ... was due to arsenic poisoning. ,Publishing results in the ...
... care clinics in China have been asked to be ... handle cases. //The Ministry of Health has also requested ... diarrhea cases. ,As Norovirus infections are highly ... in restaurants and hotels. These viruses are one of ...
... one of the most common complaints that physicians face all over ... drugs, such as Oxycontin and Vicodin // are often prescribed to ... finds that these narcotic drugs should only be used to treat ... as it would result in its abuse. ,'Opioids may ...
Cached Medicine News:Health News:Einstein's Tea Leaves Inspire New Blood Separation Technique 2Health News:Link Found Between Periodontal Disease and Pancreatic Cancer 2Health News:Mighty Conqueror Felled by Stomach Cancer 2
The Aortic Root Cannulae With Vent Line are flanged, with radiopaque tips; two side holes in tip....
The KAVD Venous Cannula is the first of its kind. It is a combination of cannulae/venous line designed to "bridge the gap between the patient and the Medtronic Resting Heart System circuit....
... Medtronic Select CAP® cannulae provides a ... pressure readings. An innovative combination of ... monitoring line, the Select CAP® can ... central arterial pressure readings on which ...
Intermittent catheter...
Medicine Products: